Spots Global Cancer Trial Database for refractory cancer
Every month we try and update this database with for refractory cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer | NCT00504790 | Cancer | GSK923295 | 18 Years - | GlaxoSmithKline | |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | NCT04510636 | Classical Hodgk... Relapsed Cancer Refractory Canc... | Pembrolizumab Bendamustine Hy... | 18 Years - | University Health Network, Toronto | |
| Molecular Profiling Protocol (SCRI-CA-001) | NCT00530192 | Refractory Canc... | Treatment based... | 18 Years - | Scottsdale Healthcare | |
| PRecISion Medicine for Children With Cancer | NCT03336931 | Childhood Cance... Childhood Solid... Childhood Brain... Childhood Leuke... Refractory Canc... Relapsed Cancer | Molecular profi... | - 21 Years | Sydney Children's Hospitals Network | |
| Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer | NCT00080418 | Neoplasm | Liposome Entrap... | 18 Years - | INSYS Therapeutics Inc | |
| Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations | NCT06229340 | RAS Mutation Ras (Kras or Nr... Colorectal Canc... Pancreas Cancer Lung Cancer Melanoma Refractory Canc... | Leflunomide The combination... | 18 Years - 85 Years | N.N. Petrov National Medical Research Center of Oncology | |
| Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer | NCT00504790 | Cancer | GSK923295 | 18 Years - | GlaxoSmithKline | |
| Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment | NCT01932047 | Refractory Canc... | - | Samsung Medical Center | ||
| Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer | NCT04337580 | Prostate Cancer Refractory Canc... Castration Resi... | Omeprazole 80 m... | 18 Years - | Wake Forest University Health Sciences | |
| Precision Medicine for Every Child With Cancer | NCT05504772 | Childhood Cance... Childhood Solid... Childhood Brain... Childhood Leuke... Refractory Canc... Relapsed Cancer | Whole Genome Se... RNA seq DNA Methylation Targeted Panel ... High Throughput... Patient Derived... Liquid Biopsy | 0 Years - 25 Years | Australian & New Zealand Children's Haematology/Oncology Group | |
| Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | NCT05856981 | Solid Tumor, Ad... Metastatic Soli... Refractory Canc... | ADU-1805 Pembrolizumab | 18 Years - | Sairopa B.V. | |
| A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | NCT05662397 | Solid Tumor, Ad... Relapsed Cancer Refractory Canc... | HST-1011 Cemiplimab | 18 Years - | HotSpot Therapeutics, Inc | |
| BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer | NCT01320280 | Refractory Canc... | BIBW 2992 (Afat... | 18 Years - | Universitätsklinikum Hamburg-Eppendorf | |
| A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer | NCT03199677 | Refractory Canc... | Apatinib | 18 Years - 75 Years | ChineseAMS | |
| IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | NCT05958121 | Refractory Canc... Recurrent Cance... Solid Tumor, Ad... Cancer | IMA402 (Phase I... IMA402 (Phase I... IMA402 (Phase I... | 18 Years - | Immatics Biotechnologies GmbH | |
| A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors | NCT04861987 | Advanced Cancer Refractory Canc... Tumor Gastric | PCS6422 and cap... | 18 Years - | Processa Pharmaceuticals | |
| Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer | NCT00100139 | Neoplasm | Liposome Entrap... Paclitaxel for ... | 18 Years - | INSYS Therapeutics Inc | |
| A Study of Avutometinib for People With Solid Tumor Cancers | NCT06104488 | Refractory Canc... CNS Tumors CNS Tumor, Adul... CNS Tumor, Chil... MAP Kinase Fami... NF1 Plexiform Neuro... Low-grade Gliom... Optic Pathway G... Neuroblastoma Primary Brain T... Solid Tumor Solid Tumor, Ad... Solid Carcinoma Central Nervous... | Avutometinib | 3 Years - 30 Years | Memorial Sloan Kettering Cancer Center | |
| Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer | NCT04840004 | Non Small Cell ... Advanced Cancer Refractory Canc... | PVT-1 | 18 Years - | PlusVitech S.L. | |
| HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA | NCT02379520 | Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... | HPV Specific T ... Cytoxan Fludarabine Nivolumab | 18 Years - | Baylor College of Medicine | |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | NCT05864144 | Solid Tumor, Ad... Advanced Solid ... Head and Neck C... Breast Cancer Colon Cancer Pancreatic Canc... Gastric Cancer Esophageal Canc... Prostate Cancer Uterine Cancer Cervix Cancer Ovarian Cancer Kidney Cancer Bladder Cancer Thyroid Cancer Melanoma Sarcoma Advanced Cancer Metastatic Canc... Refractory Canc... Non Small Cell ... | SNS-101 (anti-V... Cemiplimab | 18 Years - | Sensei Biotherapeutics, Inc. | |
| Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer | NCT04337580 | Prostate Cancer Refractory Canc... Castration Resi... | Omeprazole 80 m... | 18 Years - | Wake Forest University Health Sciences | |
| Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations | NCT06229340 | RAS Mutation Ras (Kras or Nr... Colorectal Canc... Pancreas Cancer Lung Cancer Melanoma Refractory Canc... | Leflunomide The combination... | 18 Years - 85 Years | N.N. Petrov National Medical Research Center of Oncology | |
| Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors | NCT05150457 | Refractory Soli... | BNA035 | 18 Years - | Binacea Pharma, Inc. | |
| Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | NCT05856981 | Solid Tumor, Ad... Metastatic Soli... Refractory Canc... | ADU-1805 Pembrolizumab | 18 Years - | Sairopa B.V. | |
| A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer | NCT03199677 | Refractory Canc... | Apatinib | 18 Years - 75 Years | ChineseAMS | |
| Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | NCT03941262 | Refractory Canc... Metastatic Canc... Recurrent Cance... Unresectable Ca... Solid Tumor, Ad... Advanced Cancer Advanced Solid ... | SNK01 Avelumab Pembrolizumab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer | NCT04337580 | Prostate Cancer Refractory Canc... Castration Resi... | Omeprazole 80 m... | 18 Years - | Wake Forest University Health Sciences | |
| Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations | NCT06229340 | RAS Mutation Ras (Kras or Nr... Colorectal Canc... Pancreas Cancer Lung Cancer Melanoma Refractory Canc... | Leflunomide The combination... | 18 Years - 85 Years | N.N. Petrov National Medical Research Center of Oncology | |
| Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | NCT04640246 | Cancer Tumor, Solid Refractory Canc... | TBX-3400 | 18 Years - | Taiga Biotechnologies, Inc. | |
| Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors | NCT05060276 | Relapsed Solid ... Refractory Canc... Solid Tumor, Ad... | STI-3258 | 18 Years - | Sorrento Therapeutics, Inc. | |
| Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | NCT04640246 | Cancer Tumor, Solid Refractory Canc... | TBX-3400 | 18 Years - | Taiga Biotechnologies, Inc. | |
| Molecular Profiling Protocol (SCRI-CA-001) | NCT00530192 | Refractory Canc... | Treatment based... | 18 Years - | Scottsdale Healthcare | |
| Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer | NCT00100139 | Neoplasm | Liposome Entrap... Paclitaxel for ... | 18 Years - | INSYS Therapeutics Inc | |
| Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy | NCT05990920 | Pathologically ... Refractory Canc... Metastatic Canc... Recurrent Cance... Solid Tumor, Ad... Solid Tumor Advanced Cancer Advanced Solid ... | SNK02 | 18 Years - | NKGen Biotech, Inc. | |
| A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer | NCT03206073 | Colorectal Canc... Colorectal Carc... Colorectal Aden... Refractory Canc... Colorectal Neop... | Durvalumab Tremelimumab Pexa-Vec Pexa-Vec | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents | NCT03765099 | Advanced Cancer Relapsed Cancer Refractory Canc... | Animal-Assisted... | 3 Years - 17 Years | Vanderbilt-Ingram Cancer Center | |
| Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers | NCT05302037 | Cancer Malignancy Refractory Canc... Relapsed Cancer | Allogeneic NKG2... | 21 Years - | CytoMed Therapeutics Pte Ltd | |
| 9-ING-41 in Patients With Advanced Cancers | NCT03678883 | Cancer Pancreatic Canc... Sarcoma Renal Cancer Refractory Canc... Refractory Neop... Refractory Non-... Pancreatic Aden... Resistant Cance... Neoplasm Metast... Neoplasm of Bon... Neoplasm, Breas... Neoplasm of Lun... Neoplasms,Color... Neoplasms Pancr... Malignant Gliom... Malignancies Malignancies Mu... Bone Metastases Bone Neoplasm Bone Cancer Pancreas Cancer Pancreatic Neop... Breast Neoplasm... Acute T Cell Le... | 9-ING-41 Gemcitabine - 2... Doxorubicin. Lomustine Carboplatin. Nab paclitaxel. Paclitaxel. Gemcitabine - 2... Irinotecan | 18 Years - | Actuate Therapeutics Inc. | |
| Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer | NCT00100672 | Neoplasms | LErafAON-ETU | 18 Years - | INSYS Therapeutics Inc | |
| Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer | NCT00100672 | Neoplasms | LErafAON-ETU | 18 Years - | INSYS Therapeutics Inc | |
| A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors | NCT06372574 | Refractory Canc... Recurrent Cance... Solid Tumor, Ad... | RO7617991 Tocilizumab | 18 Years - | Genentech, Inc. | |
| Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS | NCT03187288 | Acute Myeloid L... Myelodysplastic... Relapsed Cancer Refractory Canc... | CFI-400945 Fuma... | 18 Years - | University Health Network, Toronto | |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | NCT05681195 | Primary Central... Secondary Centr... Relapsed Cancer Refractory Canc... | Pemetrexed Zanubrutinib Autologous Stem... Whole Brain Rad... | 18 Years - | Baptist Health South Florida | |
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors | NCT05359445 | Refractory Canc... Recurrent Cance... Solid Tumor, Ad... Cancer | IMA401 (Phase I... IMA401 (Phase I... | 18 Years - | Immatics Biotechnologies GmbH | |
| Precision Medicine for Every Child With Cancer | NCT05504772 | Childhood Cance... Childhood Solid... Childhood Brain... Childhood Leuke... Refractory Canc... Relapsed Cancer | Whole Genome Se... RNA seq DNA Methylation Targeted Panel ... High Throughput... Patient Derived... Liquid Biopsy | 0 Years - 25 Years | Australian & New Zealand Children's Haematology/Oncology Group | |
| A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer | NCT06184035 | Solid Tumor Metastatic Canc... Unresectable So... Recurrent Solid... Locally Advance... Refractory Canc... | [177Lu]Lu-SN201 | 18 Years - | Spago Nanomedical AB | |
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors | NCT05359445 | Refractory Canc... Recurrent Cance... Solid Tumor, Ad... Cancer | IMA401 (Phase I... IMA401 (Phase I... | 18 Years - | Immatics Biotechnologies GmbH | |
| Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents | NCT04310345 | Advanced Cancer Relapsed Cancer Refractory Canc... | Animal-Assisted... | 8 Years - | Vanderbilt-Ingram Cancer Center | |
| Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | NCT06208657 | Childhood Cance... Childhood Solid... Childhood Brain... Recurrent Cance... Refractory Canc... | Paxalisib, Irin... Pimasertib | 0 Years - 21 Years | Australian & New Zealand Children's Haematology/Oncology Group | |
| Arsenic Trioxide for Structural p53 Mutations | NCT04695223 | Arsenic Trioxid... p53 Mutations Refractory Canc... Intractable Can... | Arsenic Trioxid... | 18 Years - 80 Years | Shanghai Changzheng Hospital | |
| Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer | NCT04840004 | Non Small Cell ... Advanced Cancer Refractory Canc... | PVT-1 | 18 Years - | PlusVitech S.L. | |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL | NCT04421560 | Primary Central... Recurrent Cance... Refractory Canc... Relapsed Cancer | Ibrutinib Pembrolizumab Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | NCT05681195 | Primary Central... Secondary Centr... Relapsed Cancer Refractory Canc... | Pemetrexed Zanubrutinib Autologous Stem... Whole Brain Rad... | 18 Years - | Baptist Health South Florida | |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | NCT04510636 | Classical Hodgk... Relapsed Cancer Refractory Canc... | Pembrolizumab Bendamustine Hy... | 18 Years - | University Health Network, Toronto | |
| Individualized Treatments in Adults With Relapsed/Refractory Cancers | NCT06024603 | Refractory Canc... Relapsed Cancer | Drug Sensitivit... | 18 Years - | Case Comprehensive Cancer Center | |
| Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling | NCT03760952 | Refractory Canc... Recurrent Cance... Adult Solid Tum... Neoplasms | 18 Years - | Immatics US, Inc. | ||
| Plan Development for Giving Teclistamab in the Outpatient Setting | NCT06251076 | Multiple Myelom... Relapsed Cancer Refractory Canc... | Teclistamab Tocilizumab | 18 Years - | University Health Network, Toronto | |
| A Study of GV20-0251 in Patients With Solid Tumor Malignancies | NCT05669430 | Solid Tumor, Ad... Refractory Canc... Bladder Urothel... Cholangiocarcin... Adenocarcinoma ... Endometrial Car... Head and Neck C... Cutaneous Melan... Non-small Cell ... Adenocarcinoma ... | GV20-0251 GV20-0251 | 18 Years - | GV20 Therapeutics | |
| A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors | NCT04859777 | Solid Tumor, Ad... Advanced Solid ... Advanced Cancer Metastatic Canc... Refractory Canc... | MPT-0118 MPT-0118 + pemb... | 18 Years - | Monopteros Therapeutics Inc. | |
| Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer | NCT02630199 | Refractory Canc... | AZD6738 Paclitaxel | 19 Years - | Samsung Medical Center | |
| TCR-engineered T Cells in Solid Tumors: IMA202-101 | NCT03441100 | Solid Tumor, Ad... Refractory Canc... Recurrent Cance... Cancer | IMA202 Product IMADetect® | 18 Years - | Immatics US, Inc. | |
| Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | NCT05852717 | Large Cell Lymp... Relapsed Cancer Refractory Canc... | AutoSCT OR CAR ... GDP Epcoritamab | 18 Years - | Hoosier Cancer Research Network | |
| Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | NCT04092179 | Acute Myeloid L... Relapsed Cancer Refractory Canc... IDH2 Gene Mutat... | Enasidenib Venetoclax | 18 Years - | University Health Network, Toronto | |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | NCT05864144 | Solid Tumor, Ad... Advanced Solid ... Head and Neck C... Breast Cancer Colon Cancer Pancreatic Canc... Gastric Cancer Esophageal Canc... Prostate Cancer Uterine Cancer Cervix Cancer Ovarian Cancer Kidney Cancer Bladder Cancer Thyroid Cancer Melanoma Sarcoma Advanced Cancer Metastatic Canc... Refractory Canc... Non Small Cell ... | SNS-101 (anti-V... Cemiplimab | 18 Years - | Sensei Biotherapeutics, Inc. | |
| Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer | NCT00100139 | Neoplasm | Liposome Entrap... Paclitaxel for ... | 18 Years - | INSYS Therapeutics Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
